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Acute renal failure (ARF) is a severe complication
which occurs in severely burnt patients. It has an inci-
dence of between 0.5% and 30% (depending on the
severity of the burns) [1]. Despite the advances in
modern technology and medicine, the mortality rate
is still between 73% and 100% (Table 1) [1–5].
Continuous renal replacement therapy (CRRT)
was developed for the treatment of ARF, and it has
successfully been put to use on burn patients with
ARF [1]. There are many types of CRRT, including
continuous arteriovenous hemofiltration (CAVH), con-
tinuous venovenous hemofiltration (CVVH), continu-
ous arteriovenous hemodialysis (CAVHD), continuous
venovenous hemodialysis (CVVHD), continuous ar-
teriovenous hemodiafiltration (CAVHDF), and con-
tinuous venovenous hemodiafiltration (CVVHDF).
Each type of CRRT has a specific, major function to
replace the function of the kidneys. However, which
type of CRRT is more suitable for burn patients with
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Acute renal failure (ARF) is a very common condition that may occur in patients with major burn
injuries. The majority of burn patients with ARF have a high mortality rate, ranging from 73% 
to 100%. There are several ways to treat ARF in burn patients, including peritoneal dialysis (PD),
intermittent hemodialysis, and continuous renal replacement therapy (CRRT). CRRT is generally
used in patients in whom intermittent hemodialysis has failed to control hypovolemia, as well as in
patients who cannot tolerate intermittent hemodialysis. Additionally, PD is not suitable for patients
with burns within the abdominal area. For these reasons, most patients with unstable hemodynamic
conditions receive CRRT. In this study (conducted in our burn unit between 1997 and 2004), six
burn patients received CRRT: three received continuous arteriovenous hemodialysis (CAVHD) and
the other three received continuous venovenous hemofiltration (CVVH). The patients were all
males, with a mean age of 49.8 years (range, 27–80 years), and a mean burnt surface area of 65.1%
(range, 30–95%). Four patients died due to multiple organ failure, and two patients recovered from
severe ARF. CRRT has been proven safe and useful for burn patients with ARF. According to this
study, we conclude that CVVH is an appropriate tool for treating ARF, with a lower incidence of
vascular complications than CAVHD.
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ARF is still debated. We used CAVHD and CVVH to
support our burn patients with ARF.
PATIENTS AND METHODS
Data collection
Between January 1997 and October 2003, six burn
patients with ARF were treated with CRRT at the
burn unit of Kaohsiung Medical University Hospital.
Charts on these patients were reviewed retrospec-
tively. All these patients were admitted with second
and third degree burn surface areas greater than 30%
of their total body surface area (TBSA). Factors relating
to renal failure were divided as follows: nephrotoxic
agents (aminoglycosides, vancomycin, amphotericin
B), sepsis, and hypotension (mean arterial pressure 
< 70 mmHg for 3 hours). Information about dialytic
support was also collected.
Renal replacement therapy was initiated at a serum
creatinine (Cr) level > 5.0 mg/dL or blood urea nitro-
gen (BUN) level > 70 mmol/L, or in a patient with
anuria or oliguria (urine < 350 mL/24 hours), or with
pulmonary edema not responding to diuretics.
At the beginning, all patients received fluid replace-
ment according to the Parkland formula (4 mL/kg/
%BSA/first 24 hours) with crystalloids for resusci-
tation. Colloids, such as albumin and fresh frozen
plasma, were given in the second 24 hours post-burn
period. An hourly urine output of 0.5–1 mL/kg/hour
was maintained by adjusting the infusion rate of 
fluids.
Burn wounds were covered with silver sulfadi-
azine. Surgical intervention—escharotomy, debride-
ment, or skin grafting—was performed as necessary.
Bronchoscopic examination was performed routinely
after admission to check the airway, in case inhalation
injury was suspected. Pain control as well as mild
sedation were used to make the patient comfortable.
Antibiotic therapy was given and adjusted when 
necessary.
Technical aspects of CRRT
The former three cases received CAVHD because the
rolling pump was not available at that time. CAVHD
was performed using the FH 66D (Gambro®, Germany)
filter. Vascular access was obtained via the femoral
artery and vein. The latter three patients received CVVH
treatment. The Hemofilter 6S (Gambro®, Germany)
was used for CVVH. A dual-lumen venous catheter
was inserted into the femoral vein for the vascular
routes. The hemofilter was changed when a clotting
episode occurred during CRRT. Besides this, the tubu-
lar set was changed whenever line kinking was noticed.
Heparin was used to maintain partial thromboplastin
time (PTT) within 1.5–2 times of control value.
RESULTS
All these patients were admitted to our burn center
with a burn surface area > 30% TBSA. The mean burn
surface area was 65.1% TBSA (30–95%). Three patients
had naked flame burns, two had sustained scald burns,
and one had an electrical burn injury. All these patients
were males with a mean age of 49.8 (range, 27–80
years). Four of the patients had inhalation injuries.
The renal function of these patients was normal at
the time of admission except for two patients who had
mild renal function impairment (BUN, 32–35 mmol/L;
Cr, 2.0 mg/dL). The symptoms/signs of sepsis were
noted in all six patients before progression to ARF.
The mean systolic blood pressure of the CAVHD
group (114.7mmHg) was greater than that of the CVVH
group (97 mmHg). The mean duration of CRRT was
8.2 days (4–12 days). The duration of hospitalization
was 10–57 days with a mean duration of 28.3 days.
Ventilator support was given to all six patients during
the course of CRRT.
The total mortality rate was 83.3%: multiple organ
failure (MOF) being the cause of death in four cases,
Table 1. Mortality rate and patient number in burn
patients with acute renal failure (ARF)
Burn patients Mortality, 
with ARF, n n (%)
Cason (1953–56) 49 49 (100)
Vertel et al (1960–65) 24 21 (87.5)
Guys (1953–67) 22 21 (95.4)
East Grinstead & Halton 24 20 (83.3)
(1958–79)
Davies et al (1958–79) 28 24 (86)
Cameron et al (1967) 22 21 (96)
Mercé et al (1980–82) 11 8 (73)
Leblanc et al (1987–94) 16 13 (82)
Davies et al (1990–91) 15 12 (80)
Minas et al (1990–98) 76 67 (88.1)
Holm et al (1994–98) 48 41 (85)
Kaohsiung J Med Sci July 2007 • Vol 23 • No 7346
I.F. Sun, S.S. Lee, S.D. Lin, and C.S. Lai
and cardiovascular disease in one case. Out of these
six patients, two recovered from ARF successfully.
However, only one patient survived; the other patient
expired owing to acute myocardial infarction after 
2 weeks of recovery from the course of ARF (Table 2).
There was a 33.3% recovery rate in this series.
Overview of the complications that arose in CRRT
is as follows. (1) The CAVHD group: thrombosis in one
patient; pseudoaneurysm (tube insertion site) in one
patient; two patients expressed decreased platelet
count; line disconnection in one patient; line kinking
in one patient; bleeding from the catheter insertion
wound in one patient; and hypokalemia in one patient.
(2) The CVVH group: one patient had decreased
platelet count; line kinking in one patient; filter clotting
in two patients; bleeding from the catheter insertion
wound in one patient; infection of the insertion wound
in two patients; and hypernatremia in one patient
(Table 3).
DISCUSSION
In contrast to other natural disasters, burns exert 
a catastrophic influence on people in terms of the
continuation of normal life, suffering, disability, and
the loss of finances. ARF is a major complication with
a high mortality rate in burn patients (Table 1). ARF
is defined as an abrupt decrease in the glomerular fil-
tration rate caused by intrinsic parenchymal disease
Table 2. Clinical data of the burn patients in this study
Index
Patient
1 2 3 4 5 6
Age (yr) 27 59 30 62 41 80
Sex M M M M M M
TBSA burned (%) 95 70 85 30 71 40
Type of burn Scald Flame Flame Electric Flame Scald
Inhalation injury − + + + + −
BUN (admission) (mmol/L) 15 32 20 24 16 35
Cr (admission) (mg/dL) 1.3 2.0 1.4 1.3 1.2 2.0
BUN (initiation of CRRT) (mmol/L) 147 116 87 104 122 113
Cr (initiation of CRRT) (mg/dL) 5.9 5.0 4.7 5.1 4.9 3.8
Sepsis + + + + + +
Hypotension + + + + + +
Ventilator support during CRRT + + + + + +
Duration of CRRT (d) 4 7 5 12 10 11
Type of CRRT CAVHD CAVHD CAVHD CVVH CVVH CVVH
Blood pressure (initiation of CRRT) 110/80 114/54 120/70 106/83 95/70 90/50
Duration of hospitalization (d) 14 11 10 57 28 50
Outcome Dead Dead Dead Alive Dead Dead*
*Successfully weaned from CRRT, but died from acute myocardial infarction. TBSA= total body surface area; BUN=blood urea nitrogen;
Cr = creatinine; CRRT = continuous renal replacement therapy; CAVHD = continuous arteriovenous hemodialysis; CVVH = continuous
venovenous hemofiltration.
Table 3. Complications in our continuous renal replace-
ment therapy (CRRT) patients
Complications CAVHD CVVH
Vascular
Thrombosis 1 0
Pseudoaneurysm 1 0
Vessel rupture 0 0
Blood
Platelet decrease 2 1
CRRT machine
Line disconnect 1 0
Line kinking 1 1
Filter clot 0 2
Insertion wound
Bleeding 2 1
Infection 0 2
Electrolyte imbalance 1 (hypo- 1 (hyper-
kalemia) natremia)
Fluid overload 1 0
CAVHD = continuous arteriovenous hemodialysis; CVVH =
continuous venovenous hemofiltration.
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or alternations in intrarenal hemodynamics, usually
associated with azotemia and a decrease in urine 
output [2,6].
Two forms of ARF have been described in burn
patients. The first form occurs in the first few days
after injury and is related to hypovolemia with low
cardiac output and systemic vasoconstriction during
the resuscitation period. Hauben [7] reported that the
volume of circulating plasma is reduced by 25% of
the normal value where burn areas are more than 40%
TBSA. However, this form of ARF has become less
frequent due to the aggressive resuscitation policy at
the acute stage of burn management. The other form
develops during the second week and is related to
sepsis and MOF. This form is now believed to be the
most frequent cause of renal insufficiency in burn
patients [1].
There are six etiologic factors related to the develop-
ment of ARF in burn patients: fluid shift, stress-related
hormones, myocardial depression, inflammatory medi-
ators, denatured proteins, and nephrotoxic agents
(Figure) [8–10].
Although the incidence of ARF requiring renal
replacement therapy following burn injuries is nearly
1% in the most recent series [11], dialytic support has
to be initiated early after ARF. Reported indications
include fluid overload, hyperkalemia, pulmonary
edema unresponsive to diuretics, acidosis, and uremic
complications. Although peritoneal dialysis (PD) has
been successful in the treatment of ARF, it has some
complications such as low efficiency, low rate of ultra-
filtration, the need for peritoneal access, respiratory
problems, protein losses, increased intra-abdominal
pressure, bacterial or fungal peritonitis, hernias, cath-
eter malfunction, and fluid leakage [12,13]. In addition,
it is contraindicated in abdominally injured patients,
especially in burn patients. The conventional intermit-
tent hemodialysis provides high and stable efficiency
and a high rate of ultrafiltration. However, intermit-
tent hemodialysis is associated with some complica-
tions such as post-dialytic rebound, difficulty in
balancing of solutes, cardiac arrhythmias, and severe
hypotension [13–16]. Additionally, it is contraindicated
in hypotensives and critically ill patients who cannot
leave the burn unit to go to the hemodialysis unit.
CRRT was first described by Scribner in 1960 and
was first applied to patient care by Kramer in 1977
[13,17,18]. One of the advantages of CRRT is that
hemodynamic stability is better tolerated by hypo-
tensive patients [13]. With CRRT, volume control is
continuous and immediately adaptable to the rapidly
changing clinical circumstances common in the care
of critically ill patients [18]. In addition, CRRT can cor-
rect fluid overload, improve urinary output, decrease
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Figure. Etiologic factors of renal failure in burn patients.
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neurohumoral activation, and prolong symptom-free
and edema-free time [9,18,19]. Bellomo and Ronco [19]
reported that patients treated with CRRT consistently
maintain lower urea and Cr levels. Uremic control with
CRRT is vastly superior to that achieved with standard
intermittent hemodialysis. CAVH, CVVH, CAVHD,
CVVHD, CAVHDF, and CVVHDF are all variations
of CRRT.
In this present series, CAVHD and CVVH were
used to treat the patients. CAVHD employs both dif-
fusion dialysis and convectional filtration clearance on
a continuous basis [15]. Arterial blood from an appro-
priately sized artery flows through a semipermeable
filter; dialysate is delivered to an extracorporeal com-
partment in the filter case. Within this filter case,
solutes such as urea, phosphate, and uremic toxins are
driven by their electrochemical gradient to move across
the membrane into the sterile dialysate, which is run-
ning countercurrent to blood on the other side of the
membrane capillaries [18]. CAVHD has a great ability
to remove significant quantities of circulating low mol-
ecules (BUN and Cr). Finally, clean blood flows back
to the patient through the vein. Sufficient systolic blood
pressure is needed to trigger the running of CAVHD.
The systolic blood pressure of the patients we chose
for CAVHD was > 90 mmHg.
In patients with burns exceeding 30% of TBSA,
inflammatory mediators (tumor necrosis factor-α,
interleukin-1 [IL-1], IL-6, IL-8) are released from
macrophages and other inflammatory cells due to con-
tact with microbial endotoxins or other microbial com-
ponents, causing a systemic inflammatory response
(Figure) [10]. Sepsis, the result of systemic inflamma-
tory response syndrome, may occur if the patient has
been infected [20,21]. Since CVVH has a great 
ability to remove significant quantities of circulating
macromolecules (inflammatory mediators) [17,20,22],
the effect of an efficient continuous therapy produces
a lower degree of inflammation circumstance which
blocks the progress of sepsis [6]. CVVH is an ap-
propriate tool for removing a broad spectrum of in-
flammatory mediators [15,20]. Additionally, CVVH is
triggered by a pump, so it can avoid interference caused
by the fluctuation of cardiac function.
CRRT has been in use for burn patients with ARF.
The results have improved since 1986 (Table 4) [1,4,11,
23,24]. The successful weaning CRRT rate in this patient
series was 33.3%. Because one patient suffered from
acute myocardial infarction after successful weaning
from CRRT, the overall mortality rate was 83.3%.
Despite its disadvantages and limitations, CRRT
is of great help in the treatment of burn patients with
ARF. Some of the disadvantages and limitations are as
follows: filter blockages due to a blood clot because
of hypoperfusion; bleeding at the cannulation site;
immobilization in bed; slower solute and fluid removal;
and the possibility of air embolism. Moreover, it is
contraindicated in patients with the risk of increased
intracranial pressure; there is prolonged exposure of
blood to synthetic material; anticoagulation is often
needed (that means it cannot be used in patients with
coagulopathy, liver disease, or active bleeding); and
there is the need for arterial access with CAVH,
CAVHD, or CAVHDF [4,13,16,17].
Coagulative disorders, bleeding or hematoma, arte-
riovenous fistula, thrombosis, line disconnection or
kinking, blockage of filter by clots, hypotension, cannu-
lation site infection, hypothermia, errors in electrolyte
Table 4. Mortality rate after continuous renal replacement therapy (CRRT) in different studies
ARF, n Type of CRRT Mortality, %
Hubsher et al 5 5-CAVH 80
Gueugniaud 44 12-CVVHDF, 78
6-CAVHDF
Leblanc et al 16 12-CAVHDF, 4-CAVH, 81
2-CVVHDF, 1-CVVH
Weksler et al 4 4-CVVH 23
Holm et al 48 48-CAVH 85
Tremblay et al 15 12-CVVHDF, 2-CVVH, 1-CVVHD 50
This series 6 3-CAVHD, 3-CVVH 83.3
ARF = acute renal failure; CAVH = continuous arteriovenous hemofiltration; CVVHDF = continuous venovenous hemodiafiltration;
CAVHDF = continuous arteriovenous hemodiafiltration; CVVH = continuous venovenous hemofiltration; CVVHD = continuous 
venovenous hemodialysis; CAVHD = continuous arteriovenous hemodialysis.
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and acid–base correction, fluid imbalance, and ana-
phylactic reaction are the major complications of
CRRT [13]. In this series, the complications our patients
experienced can be divided into four categories: (1)
vascular (pseudoaneurysm of femoral artery), one in
the CAVHD group; (2) manipulative error (line dis-
connection or kinking), two patients in the CAVHD
and one in the CVVH group; (3) mechanism of CRRT
(platelet decrease, filter clot, and thrombosis), three
in the CAVHD and three in the CVVH group; and (4)
problems with care (electrolyte imbalance, fluid over-
load, and wound infection), two in the CAVHD and
three in the CVVH group. After an overview of these
complications, we conclude that CVVH has a lower
incidence of vascular complications than CAVHD.
This result is comparable with that of Leblanc et al [4].
CRRT has been proven a safe and useful method
in burn patients with ARF. It is most important to initi-
ate CRRT as soon as possible once ARF has been diag-
nosed. In addition, choosing the appropriate CRRT is
another key point for successful therapy. Arteriovenous
CRRT’s reputation for bringing undesirable vascular
complications leaves venovenous CRRT as the pre-
ferred form of treatment for ARF. It is best to use con-
tinuous hemofiltration to treat ARF if the renal
function of the patient is normal before injury. If the
renal function before injury is not normal or there is 
a need to extract a large volume of fluid, continuous
hemodialysis is an appropriate consideration. Dosages
of anticoagulant must be adjusted carefully to prevent
any bleeding tendency or filter clotting formation
(check PTT and keep the patient’s normal ratio within
1.5–2; keep activated clotting time from the venous limb
within 160–200 seconds). Finally, cautious (and con-
stant) monitoring of the running of CRRT is the most
important factor that can prevent an unexpected error.
According to our preliminary experience, improve-
ment in treatment results depends on the following
suggestions. First, fluid and electrolytes should be cal-
culated carefully to prevent fluid overload or hypoten-
sive status. Second, anticoagulants should be prescribed
and adjusted cautiously to preclude any bleeding ten-
dency or filter clotting formation. Third, the tempera-
ture of the patient should be monitored carefully to
prevent hypothermia. Fourth, any sign of infection
should be watched for and antibiotic treatment should
be adjusted accordingly or if necessary. Finally, the
running of the machine should be constantly moni-
tored to avoid interrupting the CRRT.
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